Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
Harvard Business School
Mallinckrodt
Johnson and Johnson
Express Scripts

Last Updated: October 23, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for AZD-4877

See Plans and Pricing

« Back to Dashboard

Drug Development Status for AZD-4877: Patents, clinical trial progress, indications

AZD-4877 is an investigational drug.

There have been 30 clinical trials for AZD-4877. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2010.

The most common disease conditions in clinical trials are Ovarian Neoplasms, Small Cell Lung Carcinoma, and Lung Neoplasms. The leading clinical trial sponsors are AstraZeneca, National Cancer Institute (NCI), and Samsung Medical Center.

There are five US patents protecting this investigational drug and one hundred and one international patents.

Recent Clinical Trials for AZD-4877
TitleSponsorPhase
Adavosertib With or Without Olaparib in Treating Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerNational Cancer Institute (NCI)Phase 2
Adavosertib With or Without Olaparib in Treating Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerM.D. Anderson Cancer CenterPhase 2
Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian CancerAstraZenecaPhase 2

See all AZD-4877 clinical trials

Clinical Trial Summary for AZD-4877

Top disease conditions for AZD-4877
Top clinical trial sponsors for AZD-4877

See all AZD-4877 clinical trials

US Patents for AZD-4877

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AZD-4877   Start Trial Benzofuran derivatives, process for the preparation of the same and uses thereof Takeda Chemical Industries, Ltd. (Osaka, JP)   Start Trial
AZD-4877   Start Trial Benzofuran derivatives, their production and use Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
AZD-4877   Start Trial Mitotic kinesin inhibitors Merck & Co. Inc. (Rahway, NJ)   Start Trial
AZD-4877   Start Trial Benzofuran derivatives, their production and use Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
AZD-4877   Start Trial Enantiomers of selected fused heterocyclics and uses thereof AstraZeneca AB (Sodertalje, SE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AZD-4877

Drugname Country Document Number Estimated Expiration Related US Patent
AZD-4877 Austria 261435 2018-12-04   Start Trial
AZD-4877 Australia 1414600 2018-12-04   Start Trial
AZD-4877 Canada 2352786 2018-12-04   Start Trial
AZD-4877 China 1297550 2018-12-04   Start Trial
AZD-4877 China 1333764 2018-12-04   Start Trial
AZD-4877 Germany 69915508 2018-12-04   Start Trial
AZD-4877 Denmark 1136477 2018-12-04   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Express Scripts
Mallinckrodt
AstraZeneca
Medtronic
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.